- Home
- EWTX vs LILAK Comparison
EWTX vs LILAK Comparison
Compare EWTX & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- LILAK
- Stock Information
- Founded
- EWTX 2017
- LILAK 2017
- Country
- EWTX United States
- LILAK Bermuda
- Employees
- EWTX N/A
- LILAK N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- LILAK Cable & Other Pay Television Services
- Sector
- EWTX Health Care
- LILAK Telecommunications
- Exchange
- EWTX Nasdaq
- LILAK Nasdaq
- Market Cap
- EWTX 1.2B
- LILAK 1.1B
- IPO Year
- EWTX 2021
- LILAK N/A
- Fundamental
- Price
- EWTX $14.30
- LILAK $5.74
- Analyst Decision
- EWTX Buy
- LILAK Buy
- Analyst Count
- EWTX 8
- LILAK 3
- Target Price
- EWTX $39.63
- LILAK $10.27
- AVG Volume (30 Days)
- EWTX 932.9K
- LILAK 814.2K
- Earning Date
- EWTX 08-07-2025
- LILAK 08-05-2025
- Dividend Yield
- EWTX N/A
- LILAK N/A
- EPS Growth
- EWTX N/A
- LILAK N/A
- EPS
- EWTX N/A
- LILAK N/A
- Revenue
- EWTX N/A
- LILAK $4,441,000,000.00
- Revenue This Year
- EWTX N/A
- LILAK $2.45
- Revenue Next Year
- EWTX N/A
- LILAK $3.11
- P/E Ratio
- EWTX N/A
- LILAK N/A
- Revenue Growth
- EWTX N/A
- LILAK N/A
- 52 Week Low
- EWTX $10.60
- LILAK $4.23
- 52 Week High
- EWTX $38.12
- LILAK $10.93
- Technical
- Relative Strength Index (RSI)
- EWTX 41.90
- LILAK 61.02
- Support Level
- EWTX $14.87
- LILAK $5.33
- Resistance Level
- EWTX $15.68
- LILAK $5.71
- Average True Range (ATR)
- EWTX 0.67
- LILAK 0.20
- MACD
- EWTX -0.02
- LILAK 0.07
- Stochastic Oscillator
- EWTX 15.25
- LILAK 87.18
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.